AustralieFrV1, PascalFrancis, Curation, bibRecord, 004F79

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Identifieur interne : 004F79 ( PascalFrancis/Curation ); précédent : 004F78; suivant : 004F80

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Auteurs : Hervé Ghesquieres [France] ; Guillaume Cartron [France] ; John Francis Seymour [Australie] ; Marie-Hélène Delfau-Larue [France] ; Fritz Offner [Belgique] ; Pierre Soubeyran [France] ; Aurore Perrot [France] ; Pauline Brice [France] ; Réda Bouabdallah [France] ; Anne Sonet [Belgique] ; Jehan Dupuis [France] ; Olivier Casasnovas [France] ; John Vincent Catalano [Australie] ; Alain Delmer [France] ; Fabrice Jardin [France] ; Aurélie Verney [France] ; Peggy Dartigues [France] ; Gilles Salles [France]

Source :

Blood [ 0006-4971 ] ; 2012.

RBID : Pascal:12-0398695

Descripteurs français

Pascal (Inist)
- Lymphome folliculaire, Pronostic, Homme, Polymorphisme, Variabilité génétique, Génotype, Hématologie, Gène FCGR3A, Gène FCGR2A, Hémopathie maligne lymphoïde, Hémopathie lymphoïde B.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- B cell neoplasm, Follicular lymphoma, Genetic variability, Genotype, Hematology, Human, Lymphoid neoplasm, Polymorphism, Prognosis.

Abstract

In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab maintenance. In this representative patient cohort, complete and unconfirmed complete responses after rituximab chemotherapy were observed in 65%, 67%, 66% (P = .86) and 60%, 72%, 66% (P = .21) of FCGR3A VV, VF, FF and FCGR2A HH, HR, RR carriers, respectively. After 2 years of rituximab maintenance (or observation), response rates did not differ among the different genotypes. Progression-free survival measured from either treatment initiation or randomization to observation or maintenance was not influenced by these polymorphisms. These data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment. The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582.

A01	`01`	`1`		`@0 0006-4971`
A03		`1`		`@0 Blood`
A05				`@2 120`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms`
A11	`01`	`1`		`@1 GHESQUIERES (Hervé)`
A11	`02`	`1`		`@1 CARTRON (Guillaume)`
A11	`03`	`1`		`@1 SEYMOUR (John Francis)`
A11	`04`	`1`		`@1 DELFAU-LARUE (Marie-Hélène)`
A11	`05`	`1`		`@1 OFFNER (Fritz)`
A11	`06`	`1`		`@1 SOUBEYRAN (Pierre)`
A11	`07`	`1`		`@1 PERROT (Aurore)`
A11	`08`	`1`		`@1 BRICE (Pauline)`
A11	`09`	`1`		`@1 BOUABDALLAH (Réda)`
A11	`10`	`1`		`@1 SONET (Anne)`
A11	`11`	`1`		`@1 DUPUIS (Jehan)`
A11	`12`	`1`		`@1 CASASNOVAS (Olivier)`
A11	`13`	`1`		`@1 CATALANO (John Vincent)`
A11	`14`	`1`		`@1 DELMER (Alain)`
A11	`15`	`1`		`@1 JARDIN (Fabrice)`
A11	`16`	`1`		`@1 VERNEY (Aurélie)`
A11	`17`	`1`		`@1 DARTIGUES (Peggy)`
A11	`18`	`1`		`@1 SALLES (Gilles)`
A14	`01`			`@1 Centre Leon Bérard @2 Lyon @3 FRA @Z 1 aut.`
A14	`02`			`@1 Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239 @2 Lyon @3 FRA @Z 1 aut. @Z 16 aut. @Z 18 aut.`
A14	`03`			`@1 Département d'Hématologie, Centre Hospitalier Universitaire (CHU), Montpellier UMR-CNRS5235 @2 Montpellier @3 FRA @Z 2 aut.`
A14	`04`			`@1 Peter MacCallum Cancer Centre and University of Melbourne @2 Melbourne @3 AUS @Z 3 aut.`
A14	`05`			`@1 CHU Henri Mondor @2 Créteil @3 FRA @Z 4 aut. @Z 11 aut.`
A14	`06`			`@1 Ghent University @2 Ghent @3 BEL @Z 5 aut.`
A14	`07`			`@1 Institut Bergonié and Université Victor Segalen Bordeaux 2 @2 Bordeaux @3 FRA @Z 6 aut.`
A14	`08`			`@1 CHU de Nancy @2 Nancy @3 FRA @Z 7 aut.`
A14	`09`			`@1 Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris @2 Paris @3 FRA @Z 8 aut.`
A14	`10`			`@1 Institut Paoli Calmettes @2 Marseille @3 FRA @Z 9 aut.`
A14	`11`			`@1 UCL, MT-Godinne @2 Yvoir @3 BEL @Z 10 aut.`
A14	`12`			`@1 CHU de Dijon @2 Dijon @3 FRA @Z 12 aut.`
A14	`13`			`@1 Frankston Hospital @2 Frankston @3 AUS @Z 13 aut.`
A14	`14`			`@1 CHU de Reims @2 Reims @3 FRA @Z 14 aut.`
A14	`15`			`@1 Centre Henri Becquerel and UMR Inserm U918 @2 Rouen @3 FRA @Z 15 aut.`
A14	`16`			`@1 Institut Gustave Roussy @2 Villejuif @3 FRA @Z 17 aut.`
A14	`17`			`@1 Hospices Civils de Lyon @2 Pierre-Benite @3 FRA @Z 18 aut.`
A20				`@1 2650-2657`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3178 @5 354000505325150170`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 48 ref.`
A47	`01`	`1`		`@0 12-0398695`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Blood`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab maintenance. In this representative patient cohort, complete and unconfirmed complete responses after rituximab chemotherapy were observed in 65%, 67%, 66% (P = .86) and 60%, 72%, 66% (P = .21) of FCGR3A VV, VF, FF and FCGR2A HH, HR, RR carriers, respectively. After 2 years of rituximab maintenance (or observation), response rates did not differ among the different genotypes. Progression-free survival measured from either treatment initiation or randomization to observation or maintenance was not influenced by these polymorphisms. These data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment. The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582.
C02	`01`	`X`		`@0 002B19B`
C03	`01`	`X`	`FRE`	`@0 Lymphome folliculaire @5 01`
C03	`01`	`X`	`ENG`	`@0 Follicular lymphoma @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfoma folicular @5 01`
C03	`02`	`X`	`FRE`	`@0 Pronostic @5 09`
C03	`02`	`X`	`ENG`	`@0 Prognosis @5 09`
C03	`02`	`X`	`SPA`	`@0 Pronóstico @5 09`
C03	`03`	`X`	`FRE`	`@0 Homme @5 10`
C03	`03`	`X`	`ENG`	`@0 Human @5 10`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 10`
C03	`04`	`X`	`FRE`	`@0 Polymorphisme @5 11`
C03	`04`	`X`	`ENG`	`@0 Polymorphism @5 11`
C03	`04`	`X`	`SPA`	`@0 Polimorfismo @5 11`
C03	`05`	`X`	`FRE`	`@0 Variabilité génétique @5 12`
C03	`05`	`X`	`ENG`	`@0 Genetic variability @5 12`
C03	`05`	`X`	`SPA`	`@0 Variabilidad genética @5 12`
C03	`06`	`X`	`FRE`	`@0 Génotype @5 13`
C03	`06`	`X`	`ENG`	`@0 Genotype @5 13`
C03	`06`	`X`	`SPA`	`@0 Genotipo @5 13`
C03	`07`	`X`	`FRE`	`@0 Hématologie @5 14`
C03	`07`	`X`	`ENG`	`@0 Hematology @5 14`
C03	`07`	`X`	`SPA`	`@0 Hematología @5 14`
C03	`08`	`X`	`FRE`	`@0 Gène FCGR3A @4 INC @5 86`
C03	`09`	`X`	`FRE`	`@0 Gène FCGR2A @4 INC @5 87`
C03	`10`	`X`	`FRE`	`@0 Hémopathie maligne lymphoïde @4 CD @5 96`
C03	`10`	`X`	`ENG`	`@0 Lymphoid neoplasm @4 CD @5 96`
C03	`11`	`X`	`FRE`	`@0 Hémopathie lymphoïde B @4 CD @5 97`
C03	`11`	`X`	`ENG`	`@0 B cell neoplasm @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Hémopathie maligne @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Malignant hemopathy @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Hemopatía maligna @2 NM @5 37`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Lymphome non hodgkinien @5 38`
C07	`03`	`X`	`ENG`	`@0 Non Hodgkin lymphoma @5 38`
C07	`03`	`X`	`SPA`	`@0 Linfoma no Hodgkin @5 38`
C07	`04`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif @2 NM @5 39`
C07	`04`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @2 NM @5 39`
C07	`04`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @2 NM @5 39`
N21				`@1 310`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F42

Links to Exploration step

Pascal:12-0398695

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms</title>
<author><name sortKey="Ghesquieres, Herve" sort="Ghesquieres, Herve" uniqKey="Ghesquieres H" first="Hervé" last="Ghesquieres">Hervé Ghesquieres</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre Leon Bérard</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Département d'Hématologie, Centre Hospitalier Universitaire (CHU), Montpellier UMR-CNRS5235</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Delfau Larue, Marie Helene" sort="Delfau Larue, Marie Helene" uniqKey="Delfau Larue M" first="Marie-Hélène" last="Delfau-Larue">Marie-Hélène Delfau-Larue</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CHU Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Soubeyran, Pierre" sort="Soubeyran, Pierre" uniqKey="Soubeyran P" first="Pierre" last="Soubeyran">Pierre Soubeyran</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institut Bergonié and Université Victor Segalen Bordeaux 2</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Perrot, Aurore" sort="Perrot, Aurore" uniqKey="Perrot A" first="Aurore" last="Perrot">Aurore Perrot</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>CHU de Nancy</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brice, Pauline" sort="Brice, Pauline" uniqKey="Brice P" first="Pauline" last="Brice">Pauline Brice</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sonet, Anne" sort="Sonet, Anne" uniqKey="Sonet A" first="Anne" last="Sonet">Anne Sonet</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>UCL, MT-Godinne</s1>
<s2>Yvoir</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Dupuis, Jehan" sort="Dupuis, Jehan" uniqKey="Dupuis J" first="Jehan" last="Dupuis">Jehan Dupuis</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CHU Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Casasnovas, Olivier" sort="Casasnovas, Olivier" uniqKey="Casasnovas O" first="Olivier" last="Casasnovas">Olivier Casasnovas</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>CHU de Dijon</s1>
<s2>Dijon</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Catalano, John Vincent" sort="Catalano, John Vincent" uniqKey="Catalano J" first="John Vincent" last="Catalano">John Vincent Catalano</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Frankston Hospital</s1>
<s2>Frankston</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>CHU de Reims</s1>
<s2>Reims</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Jardin, Fabrice" sort="Jardin, Fabrice" uniqKey="Jardin F" first="Fabrice" last="Jardin">Fabrice Jardin</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Centre Henri Becquerel and UMR Inserm U918</s1>
<s2>Rouen</s2>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Verney, Aurelie" sort="Verney, Aurelie" uniqKey="Verney A" first="Aurélie" last="Verney">Aurélie Verney</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Hospices Civils de Lyon</s1>
<s2>Pierre-Benite</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0398695</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0398695 INIST</idno>
<idno type="RBID">Pascal:12-0398695</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F42</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004F79</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms</title>
<author><name sortKey="Ghesquieres, Herve" sort="Ghesquieres, Herve" uniqKey="Ghesquieres H" first="Hervé" last="Ghesquieres">Hervé Ghesquieres</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre Leon Bérard</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Département d'Hématologie, Centre Hospitalier Universitaire (CHU), Montpellier UMR-CNRS5235</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Delfau Larue, Marie Helene" sort="Delfau Larue, Marie Helene" uniqKey="Delfau Larue M" first="Marie-Hélène" last="Delfau-Larue">Marie-Hélène Delfau-Larue</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CHU Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Soubeyran, Pierre" sort="Soubeyran, Pierre" uniqKey="Soubeyran P" first="Pierre" last="Soubeyran">Pierre Soubeyran</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institut Bergonié and Université Victor Segalen Bordeaux 2</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Perrot, Aurore" sort="Perrot, Aurore" uniqKey="Perrot A" first="Aurore" last="Perrot">Aurore Perrot</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>CHU de Nancy</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brice, Pauline" sort="Brice, Pauline" uniqKey="Brice P" first="Pauline" last="Brice">Pauline Brice</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sonet, Anne" sort="Sonet, Anne" uniqKey="Sonet A" first="Anne" last="Sonet">Anne Sonet</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>UCL, MT-Godinne</s1>
<s2>Yvoir</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Dupuis, Jehan" sort="Dupuis, Jehan" uniqKey="Dupuis J" first="Jehan" last="Dupuis">Jehan Dupuis</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CHU Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Casasnovas, Olivier" sort="Casasnovas, Olivier" uniqKey="Casasnovas O" first="Olivier" last="Casasnovas">Olivier Casasnovas</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>CHU de Dijon</s1>
<s2>Dijon</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Catalano, John Vincent" sort="Catalano, John Vincent" uniqKey="Catalano J" first="John Vincent" last="Catalano">John Vincent Catalano</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Frankston Hospital</s1>
<s2>Frankston</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>CHU de Reims</s1>
<s2>Reims</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Jardin, Fabrice" sort="Jardin, Fabrice" uniqKey="Jardin F" first="Fabrice" last="Jardin">Fabrice Jardin</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Centre Henri Becquerel and UMR Inserm U918</s1>
<s2>Rouen</s2>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Verney, Aurelie" sort="Verney, Aurelie" uniqKey="Verney A" first="Aurélie" last="Verney">Aurélie Verney</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Hospices Civils de Lyon</s1>
<s2>Pierre-Benite</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Blood</title>
<title level="j" type="abbreviated">Blood</title>
<idno type="ISSN">0006-4971</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Blood</title>
<title level="j" type="abbreviated">Blood</title>
<idno type="ISSN">0006-4971</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B cell neoplasm</term>
<term>Follicular lymphoma</term>
<term>Genetic variability</term>
<term>Genotype</term>
<term>Hematology</term>
<term>Human</term>
<term>Lymphoid neoplasm</term>
<term>Polymorphism</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphome folliculaire</term>
<term>Pronostic</term>
<term>Homme</term>
<term>Polymorphisme</term>
<term>Variabilité génétique</term>
<term>Génotype</term>
<term>Hématologie</term>
<term>Gène FCGR3A</term>
<term>Gène FCGR2A</term>
<term>Hémopathie maligne lymphoïde</term>
<term>Hémopathie lymphoïde B</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab maintenance. In this representative patient cohort, complete and unconfirmed complete responses after rituximab chemotherapy were observed in 65%, 67%, 66% (P = .86) and 60%, 72%, 66% (P = .21) of FCGR3A VV, VF, FF and FCGR2A HH, HR, RR carriers, respectively. After 2 years of rituximab maintenance (or observation), response rates did not differ among the different genotypes. Progression-free survival measured from either treatment initiation or randomization to observation or maintenance was not influenced by these polymorphisms. These data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment. The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-4971</s0>
</fA01>
<fA03 i2="1"><s0>Blood</s0>
</fA03>
<fA05><s2>120</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GHESQUIERES (Hervé)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CARTRON (Guillaume)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SEYMOUR (John Francis)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DELFAU-LARUE (Marie-Hélène)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>OFFNER (Fritz)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SOUBEYRAN (Pierre)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>PERROT (Aurore)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BRICE (Pauline)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BOUABDALLAH (Réda)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>SONET (Anne)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>DUPUIS (Jehan)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>CASASNOVAS (Olivier)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>CATALANO (John Vincent)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>DELMER (Alain)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>JARDIN (Fabrice)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>VERNEY (Aurélie)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>DARTIGUES (Peggy)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>SALLES (Gilles)</s1>
</fA11>
<fA14 i1="01"><s1>Centre Leon Bérard</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Université Claude Bernard, Unite Mixte de Recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5239</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Département d'Hématologie, Centre Hospitalier Universitaire (CHU), Montpellier UMR-CNRS5235</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>CHU Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Institut Bergonié and Université Victor Segalen Bordeaux 2</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>CHU de Nancy</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>UCL, MT-Godinne</s1>
<s2>Yvoir</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>CHU de Dijon</s1>
<s2>Dijon</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Frankston Hospital</s1>
<s2>Frankston</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>CHU de Reims</s1>
<s2>Reims</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Centre Henri Becquerel and UMR Inserm U918</s1>
<s2>Rouen</s2>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="17"><s1>Hospices Civils de Lyon</s1>
<s2>Pierre-Benite</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA20><s1>2650-2657</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3178</s2>
<s5>354000505325150170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>48 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0398695</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Blood</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab maintenance. In this representative patient cohort, complete and unconfirmed complete responses after rituximab chemotherapy were observed in 65%, 67%, 66% (P = .86) and 60%, 72%, 66% (P = .21) of FCGR3A VV, VF, FF and FCGR2A HH, HR, RR carriers, respectively. After 2 years of rituximab maintenance (or observation), response rates did not differ among the different genotypes. Progression-free survival measured from either treatment initiation or randomization to observation or maintenance was not influenced by these polymorphisms. These data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment. The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphome folliculaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Follicular lymphoma</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfoma folicular</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Polymorphisme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Polymorphism</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Polimorfismo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Variabilité génétique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Genetic variability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Variabilidad genética</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Génotype</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Genotype</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Genotipo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Hématologie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Hematology</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hematología</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Gène FCGR3A</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Gène FCGR2A</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Hémopathie lymphoïde B</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>B cell neoplasm</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fN21><s1>310</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F79 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 004F79 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0398695
   |texte=   Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri